Management of acute ischaemic stroke in the elderly: tolerability of thrombolytics
D Tanne, D Turgeman, Y Adler - Drugs, 2001 - Springer
Stroke and its consequences are of global concern. Although stroke can affect individuals of
any age, it primarily affects the elderly. It is among the leading causes of severe disability …
any age, it primarily affects the elderly. It is among the leading causes of severe disability …
Improving low-dose blood–brain barrier permeability quantification using sparse high-dose induced prior for patlak model
Blood–brain barrier permeability (BBBP) measurements extracted from the perfusion
computed tomography (PCT) using the Patlak model can be a valuable indicator to predict …
computed tomography (PCT) using the Patlak model can be a valuable indicator to predict …
Intravenous thrombolysis in acute ischaemic stroke: optimising its use in routine clinical practice
DM Bravata - CNS drugs, 2005 - Springer
Stroke is a common and important medical problem. Intravenous thrombolysis with alteplase
(recombinant tissue plasminogen activator; rtPA) is the only available direct treatment that …
(recombinant tissue plasminogen activator; rtPA) is the only available direct treatment that …
[PDF][PDF] Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital
Background and Purpose: Tissue plasminogen activator (tPA) is a standard therapy for
acute ischemic stroke (AIS) but only limited data are noted in Taiwan. The purpose of this …
acute ischemic stroke (AIS) but only limited data are noted in Taiwan. The purpose of this …
Stroke center characteristics which influence the administration of thrombolytic therapy for acute ischemic stroke: a national survey of stroke centers in Taiwan
Stroke centers and intravenous tissue plasminogen activators (tPA) are effective
management for acute ischemic stroke. This study aimed to analyze stroke center …
management for acute ischemic stroke. This study aimed to analyze stroke center …
Hourly blood pressure monitoring after intravenous tissue plasminogen activator for ischemic stroke: does everyone need it?
V Aiyagari, A Gujjar, AR Zazulia, MN Diringer - Stroke, 2004 - Am Heart Assoc
Background and Purpose—Blood pressure (BP) control is considered essential in patients
treated with tissue plasminogen activator (tPA) for ischemic stroke, and it is recommended …
treated with tissue plasminogen activator (tPA) for ischemic stroke, and it is recommended …
Provision of stroke thrombolysis services in New Zealand: changes between 2011 and 2016
AIMS: To obtain an overall picture of the organisation of stroke thrombolysis provision in
New Zealand hospitals and compare changes between 2011 and 2016. METHODS …
New Zealand hospitals and compare changes between 2011 and 2016. METHODS …
Intravenous thrombolysis for the management of acute ischemic stroke in patients therapeutically anticoagulated with heparin: a review
G Neves, J Lee, T Bueso, V Montalvan… - Clinical Neurology and …, 2021 - Elsevier
Background Intravenous thrombolysis (IVT) with alteplase is effective in acute ischemic
stroke (AIS). However, its use rate remains low due to the many exclusion criteria. Recent …
stroke (AIS). However, its use rate remains low due to the many exclusion criteria. Recent …
rtPA 静脉治疗14 例急性脑梗死疗效观察
吴凌峰， 曹文锋， 屈新辉， 高幼奇， 刘世民， 吴晓牧 - 江西医药, 2012 - cqvip.com
目的探讨重组组织型纤溶酶原激活物(rtPA) 静脉溶栓治疗扩大时间窗至4.5 h 的疗效与安全性.
方法试验组分为治疗组和对照组, 各14 例患者. 治疗组为rtPA3h 内f6 例) 及3-4.5 h (8 例1 …
方法试验组分为治疗组和对照组, 各14 例患者. 治疗组为rtPA3h 内f6 例) 及3-4.5 h (8 例1 …
急性脑梗死超早期重组组织型纤溶酶原激活剂(r-tpA) 溶栓治疗40 例急性脑梗死临床分析
罗东辉， 张小宁， 吐尔逊 - 新疆医学, 2009 - cqvip.com
目的: 探讨重组组织型纤溶酶原激活剂(r-tpA) 治疗发病6 小时内的急性脑梗死病人的安全性和
有效性. 方法: 分析新疆医科大学第一附属医院神经内科2005 年1 月~ 2007 年12 月收治的40 …
有效性. 方法: 分析新疆医科大学第一附属医院神经内科2005 年1 月~ 2007 年12 月收治的40 …